PROLOR Biotech
Nes Ziyona
About PROLOR Biotech
PROLOR Biotech is developing proprietary versions of already-approved therapeutic proteins. The Company’s Carboxyl Terminal Peptide technology can be attached to an array of existing therapeutic proteins, stabilizing the therapy in the bloodstream and extending its lifespan without additional toxicity or loss of desired biological activity. PROLOR products under development include Human Growth Hormone (“hGH”) for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone (a $3 billion market opportunity). PROLOR’s hGH could potentially be injected once a week or twice per month instead of daily. PROLOR’s hGH is scheduled for Phase III trials in 2013.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $58.7M
- Funding stage: M&A
- Last round: Series Unknown (Apr 2012)
- Website: prolor-biotech.com
- Phone: +972866 644 7811
Industries & Categories
Biotechnology, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/prolor-biotech-1992066 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.